Controversies on Special Products for Managing Cow’s Milk Protein Allergy in Infants: Safety and Suitability
This symposium took place on 18th June 2017 as a part of the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Helsinki, Finland
Chairpersons: Antonella Muraro,1 Arne Høst2
Speakers: Rosan Meyer,3 Martinas Kuslys,4 Antonella Muraro,1 Arne Høst2
1. Department of Mother and Child Health, The Referral Centre for Food Allergy
Diagnosis and Treatment, Veneto Region, University of Padua, Padua, Italy
2. Hans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark
3. King’s College London; Imperial College London, London, UK
4. Paediatric Care Nestlé Health Science, Epalinges, Switzerland
Disclosure: Prof Antonella Muraro has received speaker’s bureau fees from Meda, Mylan, ALK, Stallergenes, Danone-Nutricia, Mead-Johnson, and Nestlè Health Science. Prof Arne Høst has received fees for lectures on the treatment of allergy from ALK-Abelló, Danone, Mead Johnson, Meda, Nestlé Health Science. Dr Rosan Meyer has received fees for academic lectures from Nestlé Health Science, Danone-Nutricia, Cow and Gate, and Mead Johnson. Dr Martinas Kuslys is an employee of Nestlé Health Science.
Acknowledgements: Writing assistance was provided by Jessica Wong, ApotheCom, London, UK.
Support: The publication of this article was funded by Nestlé Health Science for the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017. The views and opinions expressed are those of the authors and not necessarily those of Nestlé Health Science or EAACI.
Citation: EMJ Allergy and Immunol. 2017;2:46-51.
The aim of the symposium was to share learnings from the recently established European Academy of Allergy and Clinical Immunology (EAACI) Task Force on special products for cow’s milk protein allergy (CMPA), with the intention of providing an overview on controversies regarding extensively hydrolysed formulas (eHFs), their utility, and the validity of the definition ‘special products for CMPA’. Dr Rosan Meyer opened the symposium by discussing the evidence for appropriate dietary management in CMPA, emphasising the importance of breastfeeding and dietary management of breastfed children with CMPA, hypoallergenic formula, and the current controversies and debate around formula choice. Dr Martinas Kuslys covered the current interpretations and ranges for definitions for eHFs, and presented data from an analytical programme that aims to improve understanding of the wide range of commercially available formulas, with the objective of defining eHFs in a more consistent, meaningful, and practical way. Prof Antonella Muraro and Prof Arne Høst closed the session with a discussion around the need for updated guidelines to ensure safe products for infants with CMPA, summarising some of the issues with currently available hypoallergenic formulas.
This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.